Prevalent Variants in the LDLR Gene Impair Responsiveness to Rosuvastatin among Family Members of Patients with Premature Myocardial Infarction

• Published in: Journal of personalized medicine 2023-12, Vol.13 (12), p.1725
• Main Authors: Kien, Nguyen Trung, Nghia, Tran Tin, Hoang, Nguyen Minh, Phu, Tran Nguyen Trong, Nga, Pham Thi Ngoc, Mai, Ha Thi Thao, Espinoza, J Luis
• Format: Article
• Language: English
• Subjects: Cardiovascular disease; Cardiovascular diseases; Cholesterol; Families & family life; Heart attacks; Hypercholesterolemia; Intervention; LDLR gene; Lipids; Low density lipoprotein; Low density lipoprotein receptors; Metabolic disorders; Metabolism; Myocardial infarction; Patients; Precision medicine; Statins
• ISSN: 2075-4426; 2075-4426
• DOI: 10.3390/jpm13121725

Familial hypercholesterolemia (FH) is an inherited metabolic disorder characterized by high levels of low-density lipoprotein cholesterol (LDL-c) from birth. About 85% of all FH cases are caused by pathogenic variants in the LDLR gene. Individuals with FH have increased cardiovascular risk, including a high risk of premature myocardial infarction (PMI). We conducted an opportunistic exome screening to identify variants in the LDLR gene among Vietnamese patients with PMI treated at a general hospital in southern Vietnam. A cascade testing for LDLR variants was conducted in their relatives within three generations, and the effects of the LDLR variant on the response to rosuvastatin treatment were also studied using a comparative before-and-after study design on those who were eligible. A total of 99 participants from the three generations of four PMI patients were recruited, mean age 37.3 ± 18.5 years, 56.6% males. Sanger sequencing revealed two variants in the LDLR gene: variant rs577934998 (c.664T>C), detected in 17 individuals within one family, and variant rs12710260 (c.1060+10G>C), found in 32 individuals (49.5%) in the other three families tested. Individuals harboring the variant c.664T>C had significantly higher baseline LDL-c and total cholesterol levels compared to those with variant c.1060+10G>C (classified as benign) or those without LDLR variants, and among the 47 patients subjected to a 3-month course of rosuvastatin therapy, those with variant c.664T>C had a significantly higher risk of not achieving the LDL-c target after the course of treatment compared to the c.1060+10G>C carriers. These findings provide evidence supporting the existence of pathogenic LDLR variants in Vietnamese patients with PMI and their relatives and may indicate the need for personalizing lipid-lowering therapies. Further studies are needed to delineate the extent and severity of the problem.